AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update

AstraZeneca’s (AZN) fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% year over year on a reported basis and 49% at constant exchange rates (“CER”).Total revenues of $14.89 billion rose 24% on a reported basis and 25% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues beat the Zacks Consensus Estimate of $14.28 billion.All growth rates mentioned ...